Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 207-219

  Brennan, Todd V ^a   Lin, Liwen ^a   Brandstadter, Joshua D ^a   Rendell, Victoria R ^a   Dredge, Keith ^b   Huang, Xiaopei ^a   Yang, Yiping ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Progen Pharmaceuticals Limited   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; INTERLEUKIN 12; PG 545; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; CPG-OLIGONUCLEOTIDE; HEPARAN SULFATE; MYELOID DIFFERENTIATION FACTOR 88; OLIGODEOXYRIBONUCLEOTIDE; SAPONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DETERMINATION; DRUG EFFICACY; IN VIVO STUDY; LOW DRUG DOSE; LYMPHOMA; LYSOSOME; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECTS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; HEPARITIN SULFATE; HUMANS; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; LYMPHOMA; LYSOSOMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID DIFFERENTIATION FACTOR 88; OLIGODEOXYRIBONUCLEOTIDES; SAPONINS; TOLL-LIKE RECEPTOR 9;

EID: 84956673333     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI76566     Document Type: Article

References (60)

1. Wegrowski Y, Maquart FX. Involvement of stromal proteoglycans in tumour progression. Crit Rev Oncol Hematol. 2004;49(3):259-268.
2. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer. 2002;2(7):521-528.
3. Bernfield M, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729-777.
4. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci. 2000;25(8):349-351.
5. Cohen I, et al. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer. 2006;118(7):1609-1617.
6. Maxhimer JB, et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery. 2002;132(2):326-333.
7. Mikami S, et al. Expression of heparanase in renal cell carcinomas: implications for tumor invasion and prognosis. Clin Cancer Res. 2008;14(19):6055-6061.
8. Lerner I, et al. Function of heparanase in prostate tumorigenesis: potential for therapy. Clin Cancer Res. 2008;14(3):668-676.
9. Koliopanos A, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 2001;61(12):4655-4659.
10. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol. 2002;168(10):5233-5239.
11. Brennan TV, et al. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD following allogeneic stem cell transplantation. Blood. 2012;120(14):2899-2908.
12. McKenzie EA. Heparanase: A target for drug discovery in cancer and inflammation. Br J Pharmacol. 2007;151(1):1-14.
13. Ferro V, et al. Discovery of PG545: A highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J Med Chem. 2012;55(8):3804-3813.
14. Dredge K, et al. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011;104(4):635-642.
15. Hammond E, Li CP, Ferro V. Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening. Anal Biochem. 2010;396(1):112-116.
16. Ostapoff KT, et al. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol Cancer Ther. 2013;12(7):1190-1201.
17. Zhou H, et al. M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One. 2011;6(6):e21106.
18. Hammond E, Brandt R, Dredge K. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS One. 2012;7(12):e52175.
19. Basche M, et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res. 2006;12(18):5471-5480.
20. Johnstone KD, et al. Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth. J Med Chem. 2010;53(4):1686-1699.
21. Liu CJ, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. J Hepatol. 2009;50(5):958-968.
22. Joyce JA, Freeman C, Meyer-Morse N, Parish CR, Hanahan D. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene. 2005;24(25):4037-4051.
23. Ferro V, et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost. 2007;33(5):557-568.
24. Bitan M, et al. Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis. Mol Immunol. 2010;47(10):1890-1898.
25. Barash U, et al. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 2010;277(19):3890-3903.
26. Krug A, et al. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity. 2004;21(1):107-119.
27. Johnson GB, Brunn GJ, Platt JL. Cutting edge: an endogenous pathway to systemic inflammatory response syndrome (SIRS)-like reactions through Toll-like receptor 4. J Immunol. 2004;172(1):20-24.
28. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373-384.
29. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499-511.
30. Andoniou CE, et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat Immunol. 2005;6(10):1011-1019.
31. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity. 2007;26(4):503-517.
32. Latz E, et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004;5(2):190-198.
33. Honda K, et al. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature. 2005;434(7036):1035-1040.
34. Amakata Y, Fujiyama Y, Andoh A, Hodohara K, Bamba T. Mechanism of NK cell activation induced by coculture with dendritic cells derived from peripheral blood monocytes. Clin Exp Immunol. 2001;124(2):214-222.
35. Colonna M, Jonjic S, Watzl C. Natural killer cells: fighting viruses and much more. Nat Immunol. 2011;12(2):107-110.
36. Trinchieri G, Gerosa F. Immunoregulation by interleukin-12. J Leukoc Biol. 1996;59(4):505-511.
37. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13(2):155-168.
38. Lee J, et al. Nucleic acid-binding polymers as anti-inflammatory agents. Proc Natl Acad Sci USA. 2011;108(34):14055-14060.
39. Ishida K, Wierzba MK, Teruya T, Simizu S, Osada H. Novel heparan sulfate mimetic compounds as antitumor agents. Chem Biol. 2004;11(3):367-377.
40. Dredge K, et al. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs. 2010;28(3):276-283.
41. Hammond E, Handley P, Dredge K, Bytheway I. Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues. FEBS Open Bio. 2013;3:346-351.
42. Hochrein H, et al. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and-independent pathways. Proc Natl Acad Sci USA. 2004;101(31):11416-11421.
43. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Tolllike receptor-dependent and-independent pathways. J Virol. 2007;81(7):3170-3180.
44. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest. 2009;119(8):2388-2398.
45. Yamamoto S, et al. DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol. 1992;36(9):983-997.
46. Hemmi H, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408(6813):740-745.
47. Krieg AM, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995;374(6522):546-549.
48. Zhang Q, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104-107.
49. Deretic V. Autophagy in innate and adaptive immunity. Trends Immunol. 2005;26(10):523-528.
50. Oka T, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature. 2012;485(7397):251-255.
51. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet. 2005;39:359-407.
52. Escames G, et al. Mitochondrial DNA and inflammatory diseases. Hum Genet. 2012;131(2):161-173.
53. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007;117(5):1184-1194.
54. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 2012;22(2):77-89.
55. Chinnathambi S, Chen S, Ganesan S, Hanagata N. Binding mode of CpG oligodeoxynucleotides to nanoparticles regulates bifurcated cytokine induction via Toll-like receptor 9. Sci Rep. 2012;2:534.
56. Yang Y, Huang C-T, Huang X, Pardoll DM. Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol. 2004;5(5):508-515.
57. Cheadle EJ, et al. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol. 2010;184(4):1885-1896.
58. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002;295(5556):868-872.
59. Brennan TV, et al. A new T-cell receptor transgenic model of the CD4+ direct pathway: level of priming determines acute versus chronic rejection. Transplantation. 2008;85(2):247-255.
60. Oppmann B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715-725.